De 6 a 8 ONG tendrán la oportunidad de presentar su trabajo y su posición sobre este tema durante esta reunión de dos horas. Más información, en inglés, está disponible abajo. 


The INCB's thematic hearing in 2022 will focus on analysing the trend to legalise the non-medical use of drugs with an emphasis on cannabis. The hearing will take place in the margins of the 134th INCB session 23 May to 3 June (exact date and time to be confirmed).


Civil society participation

The International Narcotics Control Board (INCB) will host a civil society hearing for the INCB board members in the margins of the 134th session. The hearing will be on the topic of "analysis of the trend to legalise the non-medical use of drugs with an emphasis on cannabis" and will take place online or in a hybrid format in the period between 23 May and 3 June. The exact date and time will be communicated as soon as possible. 

6 to 8 NGOs will have the possibility to present their work and positioning on this issue during the two hour meeting. In order to ensure an inclusive, comprehensive and meaningful civil society participation, the VNGOC will once again coordinate and select contributions from around the world. The VNGOC will follow our established guidelines to do this. Indigenous applications are welcome. 

Each speaker will have 5-7 minutes to present their work on the topic of "analysis of the trend to legalise the non-medical use of drugs with an emphasis on cannabis". Selected speakers will be asked to send in their statements before the hearing. All abstracts have to be submitted in English.

In order to apply for a speaking slot, please fill out and submit this form (https://bit.ly/3E3GGe5) by 4th May 2022 11.45 pm CEST, Vienna local time. Selected candidates will be notified as soon as possible.

Please share this with your respective partners and networks to ensure a wide as possible opportunity to engage. 

Thank you and looking forward to your applications. Do not hesitate to contact us at info@vngoc.org in case you have any questions.